New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2014
06:23 EDTAKRXAkorn guidance 'not a cause for alarm,' says Piper Jaffray
Piper Jaffray believes Akorn's 2014 guidance is "not a cause for alarm" given the depth of the company's pipeline. Piper says Akorn's long-term growth story remains intact and it keeps an Overweight rating on the stock despite lowering its price target for shares to $28 from $29.
News For AKRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2015
17:51 EDTAKRXS&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices
Subscribe for More Information
17:22 EDTAKRXUnited Insurance to replace Akorn in S&P 600 as of 1/30 close
17:21 EDTAKRXAkorn to replace Protective Life in S&P 400 as of 1/30 close
Subscribe for More Information
January 26, 2015
07:05 EDTAKRXAkorn price target raised to $55 from $45 at Piper Jaffray
Piper Jaffray raised its price target for Akorn shares to $55 saying approvals of "seemingly minor" abbreviated New Drug Application opportunities, like last week's Phenylephrine Hydrochloride Ophthalmic Solution, could in the aggregate drive significant upside to consensus estimates in 2015 and beyond. Piper reiterates an Overweight rating on shares of Akorn.
January 20, 2015
08:09 EDTAKRXAkorn price target raised to $49 from $44 at Jefferies
Jefferies raised its price target for Akorn shares to $49 to reflect its FY15 estimates. The firm keeps a Buy rating on the stock.
07:11 EDTAKRXAkorn receives FDA approval for Phenylephrine Hydrochloride Ophthalmic Solution
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use